Objective: The aim of this study was to assess the pomegranate juice against the growth and toxin production of multidrug-resistant Clostridium difficile hypervirulent strain NAP1/027/BI and also against the growth of beneficial bacteria to prevent or suppress C. difficile infection (CDI). Materials and methods: Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were taken as parameters for the assessment of antimicrobial property of the pomegranate juice. Four different C. difficile hypervirulent strains NAP1/027/BI, Lac-tococcus lactis spp., Lactobacillus casei, and Bifidobacterium animalis were subjected to the broth dilution method to determine the MIC and MBC. Enzyme-linked immunosorbent assay (ELISA) was performed to determine clostridial toxin B (TcdB) production in the presence of pomegranate juice. Results: The MIC and MBC of pomegranate juice containing punicalagin were found to be 390 µg/mL for all C. difficile hypervirulent strain NAP1/027/BI, and the growth of L. lactis spp., L. casei, and B. animalis was not inhibited. Pomegranate juice reduced TcdB production in C. difficile hypervirulent strain NAP1/027/BI. Conclusion: This study highlights the potential of pomegranate juice to reduce CDI without affecting the beneficial bacteria. Pomegranate juice may be a useful antimicrobial agent to prevent or suppress CDI, avoiding the use of antibiotics.
CITATION STYLE
Sukumar, M. R., & König, B. (2018). Pomegranate extract specifically inhibits Clostridium difficile growth and toxin production without disturbing the beneficial bacteria in vitro. Infection and Drug Resistance, 11, 2357–2362. https://doi.org/10.2147/IDR.S163484
Mendeley helps you to discover research relevant for your work.